{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:11:46Z","timestamp":1788293506662,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.iac.2024.07.007","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T11:05:42Z","timestamp":1728385542000},"page":"737-750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma"],"prefix":"10.1016","volume":"44","author":[{"given":"Mauli","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Haines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.iac.2024.07.007_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: Selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.iac.2024.07.007_bib3","article-title":"Omalizumab","author":"Kumar","year":"2023","journal-title":"StatPearls"},{"issue":"3","key":"10.1016\/j.iac.2024.07.007_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.iac.2024.07.007_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.iac.2024.07.007_bib6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1398-9995.2010.02522.x","article-title":"Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma","volume":"66","author":"Bousquet","year":"2011","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.iac.2024.07.007_bib7","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2024.07.007_bib8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1378\/chest.12-1372","article-title":"Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma","volume":"143","author":"Grimaldi-Bensouda","year":"2013","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.iac.2024.07.007_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1710-1492-9-47","article-title":"Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting","volume":"9","author":"Braunstahl","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2024.07.007_bib10","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jaip.2017.02.002","article-title":"\"Real-life\" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis","volume":"5","author":"Alhossan","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.07.007_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study","volume":"7","author":"Casale","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.iac.2024.07.007_bib12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.iac.2024.07.007_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2024.07.007_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/JAA.S236609","article-title":"Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs","volume":"13","author":"Llanos","year":"2020","journal-title":"J\u00a0Asthma Allergy"},{"issue":"10","key":"10.1016\/j.iac.2024.07.007_bib15","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.iac.2024.07.007_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02345-2019","article-title":"Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme","volume":"55","author":"Taill\u00e9","year":"2020","journal-title":"Eur Respir J"},{"issue":"15","key":"10.1016\/j.iac.2024.07.007_bib17","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study","volume":"81","author":"Domingo","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.iac.2024.07.007_bib18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.anai.2021.05.021","article-title":"Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities","volume":"127","author":"Casale","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.iac.2024.07.007_bib19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/cea.13882","article-title":"Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes","volume":"51","author":"Fong","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.iac.2024.07.007_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-World Effectiveness and the Characteristics of a \"Super-Responder\" to Mepolizumab in Severe Eosinophilic Asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.iac.2024.07.007_bib21","doi-asserted-by":"crossref","first-page":"101836","DOI":"10.1016\/j.pupt.2019.101836","article-title":"One year of mepolizumab. Efficacy and safety in real-life in Italy","volume":"58","author":"Bagnasco","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.iac.2024.07.007_bib22","doi-asserted-by":"crossref","first-page":"102130","DOI":"10.1016\/j.pupt.2022.102130","article-title":"Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan","volume":"75","author":"Nagase","year":"2022","journal-title":"Pulm Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.iac.2024.07.007_bib23","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1016\/j.jaip.2023.07.024","article-title":"Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis","volume":"11","author":"Liu","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2024.07.007_bib24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.iac.2024.07.007_bib25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.anai.2022.02.017","article-title":"Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study","volume":"128","author":"Chung","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.iac.2024.07.007_bib26","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jaip.2023.04.029","article-title":"Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2","volume":"11","author":"Carstens","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.07.007_bib27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12931-019-1251-3","article-title":"The effectiveness of Reslizumab in severe asthma treatment: a real-world experience","volume":"20","author":"Ibrahim","year":"2019","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.iac.2024.07.007_bib28","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.chest.2020.11.060","article-title":"Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice","volume":"159","author":"Wechsler","year":"2021","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.iac.2024.07.007_bib29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cea.14112","article-title":"Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis","volume":"52","author":"Charles","year":"2022","journal-title":"Clin Exp Allergy"},{"issue":"26","key":"10.1016\/j.iac.2024.07.007_bib30","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.iac.2024.07.007_bib31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy\/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.iac.2024.07.007_bib32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cea.13614","article-title":"Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort","volume":"50","author":"Dupin","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2024.07.007_bib33","article-title":"Real-world effectiveness of dupilumab in patients with asthma: Findings from the US advantage study","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2024.07.007_bib34","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2147\/JAA.S328988","article-title":"Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis","volume":"14","author":"Pelaia","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"issue":"19","key":"10.1016\/j.iac.2024.07.007_bib35","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2 Supplement","key":"10.1016\/j.iac.2024.07.007_bib36","doi-asserted-by":"crossref","first-page":"AB21","DOI":"10.1016\/j.jaci.2022.12.068","article-title":"Tezepelumab-ekko Improved Asthma Control and Asthma Symptom in Adults with Uncontrolled and Severe Asthma in Real-Life","volume":"151","author":"Gupta","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2 Supplement","key":"10.1016\/j.iac.2024.07.007_bib37","doi-asserted-by":"crossref","first-page":"AB96","DOI":"10.1016\/j.jaci.2023.11.318","article-title":"The Real-world Effectiveness of Tezepelumab in a Cohort of Patients with Severe Asthma","volume":"153","author":"Nopsopon","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2 Supplement","key":"10.1016\/j.iac.2024.07.007_bib38","doi-asserted-by":"crossref","first-page":"AB102","DOI":"10.1016\/j.jaci.2023.11.334","article-title":"Real-Life Tezepelumab-ekko Study On The Effectiveness Of Asthma Control And Patient Characteristics In Adults And Adolescents With Severe Uncontrolled Asthma","volume":"153","author":"Gomez","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2024.07.007_bib39","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/all.13850","article-title":"The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma","volume":"74","author":"Chapman","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2024.07.007_bib40","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1038\/s41598-021-84895-2","article-title":"Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma","volume":"11","author":"Carpagnano","year":"2021","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.iac.2024.07.007_bib41","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.jaip.2022.04.014","article-title":"Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma - First Initiators and Switchers","volume":"10","author":"Hashimoto","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2024.07.007_bib42","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/JAA.S270298","article-title":"Switch from IL-5 to IL-5-Receptor \u03b1 Antibody Treatment in Severe Eosinophilic Asthma","volume":"13","author":"Drick","year":"2020","journal-title":"J\u00a0Asthma Allergy"},{"issue":"1","key":"10.1016\/j.iac.2024.07.007_bib43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s12890-021-01785-z","article-title":"Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)","volume":"21","author":"Mart\u00ednez-Morag\u00f3n","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"12","key":"10.1016\/j.iac.2024.07.007_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9121822","article-title":"Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy","volume":"9","author":"Pelaia","year":"2021","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.iac.2024.07.007_bib45","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaip.2020.09.014","article-title":"Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy","volume":"9","author":"M\u00fcmmler","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.iac.2024.07.007_bib46","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jaip.2022.11.043","article-title":"Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma","volume":"11","author":"Pavord","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2024.07.007_bib47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/JAA.S357548","article-title":"Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study","volume":"15","author":"Numata","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"issue":"5","key":"10.1016\/j.iac.2024.07.007_bib48","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.anai.2018.09.297","article-title":"Combination biologic therapy in severe asthma: a case series","volume":"121","author":"Thomes","year":"2018","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T12:26:52Z","timestamp":1729600012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856124000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0889856124000560"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2024.07.007","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2024.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}